Last reviewed · How we verify
inactive ingredients capsule
At a glance
| Generic name | inactive ingredients capsule |
|---|---|
| Sponsor | Laboratorio Farmaceutico Ct S.r.l. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pyrexia
- Nausea
- Vomiting
- Cough
- Abdominal pain
- Headache
- Pruritus
- Diarrhoea
- Urticaria
- Rash
- Fatigue
- Throat irritation
Key clinical trials
- Effect of L. Reuteri LM1063 on Sleep Health Improvement (NA)
- The Acute Effects of Onnit Alpha Brain on Cognition and Mood States (NA)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in Obesity (NA)
- Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder (EARLY_PHASE1)
- A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis (NA)
- Phase I Trial of Defactinib and VS-6766. (PHASE1)
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- inactive ingredients capsule CI brief — competitive landscape report
- inactive ingredients capsule updates RSS · CI watch RSS
- Laboratorio Farmaceutico Ct S.r.l. portfolio CI